Fibrolase
Latest Information Update: 15 Aug 2007
Price :
$50 *
At a glance
- Originator Chiron Corporation
- Class Metalloendopeptidases; Thrombolytics
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 05 Nov 1997 No-Development-Reported for Thrombosis in USA (Unknown route)
- 16 Jan 1995 Preclinical development for Thrombosis in USA (Unknown route)